A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma

Trial Profile

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs AMG 232 (Primary)
  • Indications Multiple myeloma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Amgen
  • Most Recent Events

    • 04 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 02 Dec 2016 Results presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    • 26 Sep 2016 Planned End Date changed from 1 May 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top